Pain Therapeutics, Inc. (NASDAQ:PTIE) stock price target upped to $2.75, reported today by Zacks Investment Research
- Updated: September 16, 2016
Showing a price of $2.54, Pain Therapeutics, Inc. (NASDAQ:PTIE) traded 9.48% higher on the day. With the last stock close up 10.25% relative to the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. Pain Therapeutics, Inc. has registered a 50-day moving average of $2.49 and two hundred day moving average of $2.30. 516,223 shares of PTIE traded hands, up from ann avg. volume of 145,805
Pain Therapeutics, Inc. (NASDAQ:PTIE) had its price target upped to $3 by Zacks Investment Research in a report released 9/17/2016. The increased target price implies a possible upside of 0.08% from the bussiness’ most recent stock close price.
Previously on Tuesday September 13 2016, Gabelli released a statement for Pain Therapeutics, Inc.(NASDAQ:PTIE) upped the target price from $0.00 to $2.50 that indicated a possible downside of -0.02%.
Pain Therapeutics, Inc. has a one-year low of $1.55 and a one-year high of $2.77 . The company’s market capitalization is currently $0.0.
Brief Synopsis About Pain Therapeutics, Inc. (NASDAQ:PTIE)
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, and abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.